journal article·2024-07Open access

Prostate‐Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer

Niranjan Meher, Gary W. Ashley, Kondapa Naidu Bobba, Anju Wadhwa, Anil P. Bidkar, Chandrashekhar Dasari, Changhua Mu, Ramya Ambur Sankaranarayanan, Juan A. Camara Serrano, Athira Raveendran, David P. Bulkley, Rahul Aggarwal, Nancy Y. Greenland, Adam Oskowitz, David M. Wilson, Youngho Seo, Daniel V. Santi, Henry F. VanBrocklin, Robert R. Flavell

Advanced Healthcare Materials· Volume 13· Issue 19

Abstract

Abstract The tumor uptake of large non‐targeted nanocarriers primarily occurs through passive extravasation, known as the enhanced permeability and retention (EPR) effect. Prior studies demonstrated improved tumor uptake and retention of 4‐arm 40 kDa star polyethylene glycol (StarPEG) polymers for cancer imaging by adding prostate‐specific membrane antigen (PSMA) targeting small molecule ligands. To test PSMA‐targeted delivery and therapeutic efficacy, StarPEG nanodrugs with/without three copies of PSMA‐targeting ligands, ACUPA, are designed and synthesized. For single‐photon emission computed tomography (SPECT) imaging and therapy, each nanocarrier is labeled with 177Lu using DOTA radiometal chelator. The radiolabeled nanodrugs, [177Lu]PEG‐(DOTA)1 and [177Lu]PEG‐(DOTA)1(ACUPA)3, are evaluated in vitro and in vivo using PSMA+ PC3‐Pip and/or PSMA– PC3‐Flu cell lines, subcutaneous xenografts and disseminated metastatic models. The nanocarriers are efficiently radiolabeled with 177Lu with molar activities 10.8–15.8 MBq/nmol. Besides excellent in vitro PSMA binding affinity (kD = 51.7 nM), the targeted nanocarrier, [177Lu]PEG‐(DOTA)1(ACUPA)3, demonstrated excellent in vivo SPECT imaging contrast with 21.3% ID/g PC3‐Pip tumors uptake at 192 h. Single doses of 18.5 MBq [177Lu]PEG‐(DOTA)1(ACUPA)3 showed complete resolution of the PC3‐Pip xenografts observed up to 138 days. Along with PSMA‐targeted excellent imaging contrast, these results demonstrated high treatment efficacy of [177Lu]PEG‐(DOTA)1(ACUPA)3 for prostate cancer, with potential for clinical translation.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Radiopharmaceutical Chemistry and Applications · Prostate Cancer Treatment and Research · Electron and X-Ray Spectroscopy Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Radiology and Biomedical Imaging University of California San Francisco CA 94143 USA

National Institute of Pharmaceutical Education and Research Raebareli Lucknow UP 226002 India

ProLynx Inc. San Francisco CA 94158 USA

Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco CA 94143‐0981 USA

Division of Vascular and Endovascular Surgery University of California San Francisco CA 94143‐0957 USA

Department of Pathology University of California San Francisco CA 94143 USA

Department of Pharmaceutical Chemistry University of California San Francisco CA 94158‐2517 USA

Department of Biochemistry and Biophysics University of California San Francisco CA 94158 USA

Funding

Science, Mathematics, And Research For Transformation Scholarship Program

References (38)

Show source-provided references
1. 10.1002/sstr.20220003610.1002/sstr.202200036 ↗
2. 10.1073/pnas.050210110210.1073/pnas.0502101102 ↗
3. 10.2967/jnumed.121.26319510.2967/jnumed.121.263195 ↗
4. 10.2174/187447101266619072915154010.2174/1874471012666190729151540 ↗
5. 10.1080/14737140.2020.181415110.1080/14737140.2020.1814151 ↗
6. 10.1039/C3CS60304K10.1039/C3CS60304K ↗
7. 10.1007/s00259010063910.1007/s002590100639 ↗
8. 10.1177/2050312121103436610.1177/20503121211034366 ↗
9. 10.3390/ph1602031510.3390/ph16020315 ↗
10. 10.1016/S0168-3659(99)00248-510.1016/S0168-3659(99)00248-5 ↗
11. 10.1016/j.addr.2015.01.00210.1016/j.addr.2015.01.002 ↗
12. 10.7150/thno.3677710.7150/thno.36777 ↗
13. 10.1021/acsnano.5b0132410.1021/acsnano.5b01324 ↗
14. 10.1158/1535-7163.MCT-19-070910.1158/1535-7163.MCT-19-0709 ↗
15. 10.1021/acsami.2c1509510.1021/acsami.2c15095 ↗
16. 10.3390/biom909042110.3390/biom9090421 ↗
17. 10.2967/jnumed.110.08399810.2967/jnumed.110.083998 ↗
18. 10.1021/nn301725w10.1021/nn301725w ↗
19. 10.1021/acs.molpharmaceut.9b0018110.1021/acs.molpharmaceut.9b00181 ↗
20. 10.1021/acsami.1c1638310.1021/acsami.1c16383 ↗
21. 10.1016/j.nucmedbio.2016.05.00610.1016/j.nucmedbio.2016.05.006 ↗
22. 10.1186/s41181-021-00130-310.1186/s41181-021-00130-3 ↗
23. M.Evans Y.Huang C.Drake 20220280661 2022.
24. 10.2967/jnumed.118.21935210.2967/jnumed.118.219352 ↗
25. 10.1039/b901970g10.1039/b901970g ↗
26. 10.7150/thno.1871910.7150/thno.18719 ↗
27. Maus S. · Int. J. · 2014 · 1 · 5
28. 10.1007/s00259-020-05057-610.1007/s00259-020-05057-6 ↗
29. 10.1021/acs.molpharmaceut.9b0046410.1021/acs.molpharmaceut.9b00464 ↗
30. 10.1158/1078-0432.CCR-20-331010.1158/1078-0432.CCR-20-3310 ↗
31. 10.1107/S090744490700902X10.1107/S090744490700902X ↗
32. 10.1021/jm800994j10.1021/jm800994j ↗
33. 10.1007/s00259-022-05933-310.1007/s00259-022-05933-3 ↗
34. 10.1007/s00259-022-05727-710.1007/s00259-022-05727-7 ↗
35. 10.1007/s00259-022-05837-210.1007/s00259-022-05837-2 ↗
36. Manuel C. A. · J. Am. Assoc. Lab. Anim. Sci. · 2017 · 56 · 202
37. 10.2967/jnumed.118.22115010.2967/jnumed.118.221150 ↗
38. 10.1158/1078-0432.CCR-22-329110.1158/1078-0432.CCR-22-3291 ↗